Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Anesthesia

PUBLISHER: Grand View Research | PRODUCT CODE: 1553460

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1553460

Local Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Bupivacaine, Ropivacaine, Lidocaine), By Application (Injectable, Surface Anesthetic), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Local Anesthesia Drugs Market Growth & Trends:

The global local anesthesia drugs market size is anticipated to reach USD 5.14 billion in 2030 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. The rising number of surgical procedures across the globe, including cosmetic surgeries, dental procedures, and plastic surgeries, is driving the growth of local anesthetics.

There has been a considerable increase in the number of surgical procedures requiring post-operative pain relief and this trend is expected to continue throughout the forecast period. Roughly, 65.0% of total surgical procedures require post-operative pain management. This is likely to boost the demand for local anesthesia drugs.

The introduction of new and effective drugs such as levobupivacaine, articaine, and ropivacaine is also driving the growth of the local anesthesia drugs market across the globe. Rising healthcare expenditure in developing countries is expected to result in an increase in the number of surgeries performed in countries such as India, China, and Brazil. This is likely to contribute to market growth in the region.

Local Anesthesia Drugs Market Report Highlights:

  • Lidocaine dominated the market by product as of 2016 owing to its extensive use as a topical and injectable anesthetic
  • By application, the market is bifurcated into injectable and surface anesthetic. The injectable segment is expected to dominate the local anesthesia drugs market during the forecast period owing to extensive usage in different surgical procedures. Advancements in drug delivery systems are expected to drive the market for surface anesthetics over the forecast period
  • North America held the largest share in the market for local anesthesia drugs owing to a significant number of surgical procedures performed in the region
  • Some of the key players are Aspen Pharmacare; Fresenius Kabi; Novartis, Inc.; Sagent Pharmaceutical; Pacira Pharmaceutical; Mylan; and Teva Pharmaceuticals.
Show more
Product Code: GVR-2-68038-086-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Local Anesthesia Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Local Anesthesia Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Local Anesthesia Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Local Anesthesia Drugs Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Bupivacaine
    • 4.3.1. Bupivacaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ropivacaine
    • 4.4.1. Ropivacaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lidocaine
    • 4.5.1. Lidocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Chloroprocaine
    • 4.6.1. Chloroprocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Prilocaine
    • 4.7.1. Prilocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Benzocaine
    • 4.8.1. Benzocaine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Local Anesthesia Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Local Anesthesia Drugs Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Injectable
    • 5.3.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Surface Anesthetic
    • 5.4.1. Surface Anesthetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Local Anesthesia Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Local Anesthesia Drugs Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.K.
      • 6.3.2.1. U.K. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Sweden Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. India Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. South Korea Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Local Anesthesia Drugs and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Local Anesthesia Drugs Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Johnson & Johnson Services, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. AstraZeneca plc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Novartis AG.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Teva Pharmaceutical Industries Ltd.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. GlaxoSmithKline plc
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Sanofi S.A.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck & Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Aspen Pharmacare Holdings Limited
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Mylan N.V.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!